EUVIMEDEUVIMED entdecken
Crossref

Application of the Heidelberg Prognostic Pancreatic Cancer Score for Survival Risk Stratification in Stage II/III Colorectal Cancer

Masayuki Urabe iD, Masaya Hiyoshi, Mami Suzuki, Takahiro Fukai, Yui Hasegawa, Emi Terai, Yoshitaka Kiya, Goki Morizono, Toshiyuki Watanabe, Yojiro Hashiguchi

The American Surgeon™ · 2026-12 · 92 (12) · 3269-3275

DOI: 10.1177/00031348261465407 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The American Surgeon™, online erschienen am 26.06.2026. Verfasst von Masayuki Urabe und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gastrointestinal Surgery Division, Department of Surgery, Japanese Red Cross Omori Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Reliable and broadly applicable tools for survival risk stratification in stage II/III colorectal cancer (CRC) remain limited. The Heidelberg prognostic pancreatic cancer (HELPP) score is a multidimensional index integrating tumor burden, systemic inflammation, nutritional status, and host physiological condition, and has been well validated for prognostication in pancreatic cancer. We hypothesized that this score would also be applicable to CRC and investigated its prognostic utility.

Methods

A consecutive cohort of 481 patients with pathological stage II/III CRC undergoing curative resection was retrospectively interrogated. The prognostic impact of the HELPP score was assessed using Kaplan-Meier estimates and Cox proportional hazards modeling.

Results

With a median follow-up of 65 months, 129 patients died. Kaplan-Meier analyses demonstrated clear and consistent stratification of both overall survival (OS) and relapse-free survival (RFS) according to the HELPP score. In univariate analyses, a HELPP score >3 was significantly associated with worse OS and RFS. Importantly, this association remained robust after adjustment for clinically relevant covariates, with HELPP score >3 independently predicting OS (hazard ratio [HR] 1.99, 95% confidence interval [CI] 1.25-3.18, P = 0.004) and RFS (HR 1.78, 95% CI 1.19-2.66, P = 0.005).

Discussion

The HELPP score delivers robust, independent prognostic stratification in stage II/III CRC and represents a practical, clinically actionable tool for refined risk assessment. Its integration into clinical practice may enable more precise tailoring of adjuvant therapy and surveillance, advancing individualized management in CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsHumansRetrospective StudiesFemaleNeoplasm StagingPrognosisMaleRisk AssessmentAgedMiddle AgedKaplan-Meier EstimateProportional Hazards ModelsAged, 80 and over

Stichwörter der Autor:innen

Heidelberg prognostic pancreatic cancer scorecolorectal cancerprognosissurgery

Autor:innen und Institutionen

  • Gastrointestinal Surgery Division, Department of Surgery, Japanese Red Cross Omori Hospital, Tokyo, Japan.

ORCID-Profile: Masayuki Urabe

Zitieren

APA

Urabe, M., Hiyoshi, M., Suzuki, M., Fukai, T., Hasegawa, Y., Terai, E., Kiya, Y., Morizono, G., Watanabe, T., & Hashiguchi, Y. (2026). Application of the Heidelberg Prognostic Pancreatic Cancer Score for Survival Risk Stratification in Stage II/III Colorectal Cancer. The American Surgeon™, 92(12), 3269-3275. https://doi.org/10.1177/00031348261465407

Vancouver

Urabe M, Hiyoshi M, Suzuki M, Fukai T, Hasegawa Y, Terai E, et al. Application of the Heidelberg Prognostic Pancreatic Cancer Score for Survival Risk Stratification in Stage II/III Colorectal Cancer. The American Surgeon™. 2026;92(12):3269-3275. doi:10.1177/00031348261465407

BibTeX
@article{Urabe2026,
  author = {Urabe, Masayuki and Hiyoshi, Masaya and Suzuki, Mami and Fukai, Takahiro and Hasegawa, Yui and Terai, Emi and Kiya, Yoshitaka and Morizono, Goki and Watanabe, Toshiyuki and Hashiguchi, Yojiro},
  title = {Application of the Heidelberg Prognostic Pancreatic Cancer Score for Survival Risk Stratification in Stage II/III Colorectal Cancer},
  journal = {The American Surgeon™},
  year = {2026},
  volume = {92},
  number = {12},
  pages = {3269--3275},
  doi = {10.1177/00031348261465407}
}
Kostenlos starten →